You are here

  • Home
  • Online First
  • ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation

Citation Tools

Article menu

other Versions

Download PDFPDF
Clinical trial
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation

Download to a citation manager

Download the citation for this article by clicking on one of the following citation managers:

Cite this article as:
Garcia-Duran C, Grau F, Villacampa G, et al
ATOMICC trial: a randomized, open-label, phase II trial of anti-PD1, dostarlimab, as maintenance therapy for patients with high-risk locally advanced cervical cancer after chemoradiation
International Journal of Gynecologic Cancer Published Online First: 20 April 2022. doi: 10.1136/ijgc-2022-003370